Find clinical trials for Adenocarcinoma in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma

Pancreatic Cancer

Colorectal Cancer

Stomach Cancer

Esophageal Cancer

Cancer

Prostatic Cancer

Adenocarcinoma trials near Berlin, BE, DEU:

Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

plus trastuzumab alone for a maximum systemic treatment duration of one year in patients with Her-2 positive localized esophagogastric adenocarcinoma...

Active, not recruiting

Esophagogastric Adenocarcinoma

Drug: Pembrolizumab

Drug: Trastuzumab

Phase 2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Berlin, Germany and 12 other locations

Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma (NeoART)

trastuzumab-deruxtecan containing combinational treatment regimens in patients with HER2 positive, locally advanced, resectable esophagogastric adenocarcinoma...

Enrolling

Esophagogastric Adenocarcinoma

Drug: Trastuzumab deruxtecan + 5FU/LV

Drug: Trastuzumab deruxtecan + FLO

Phase 1, Phase 2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Berlin, Germany and 10 other locations

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Active, not recruiting

Gastric Cancer, Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma

Drug: Ramucirumab

Drug: Paclitaxel

Phase 3

Daiichi Sankyo

Berlin, Germany and 155 other locations

Status recently updated

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015)

(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...

Enrolling

Active, not recruiting

Gastroesophageal Cancer

Drug: Rescue medication

Drug: Supportive care measures

Phase 3

Merck Sharp & Dohme (MSD)

Berlin, Germany and 167 other locations

Locations recently updated

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients (ZANGEA)

and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma (GEA). The patients need to be previously untreated in the pall...

Enrolling

Gastroesophageal Adenocarcinoma

PDL-1

Drug: Pembrolizumab

Drug: Zanidatamab

Phase 2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Berlin, Germany and 19 other locations

Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

response in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. The main questi...

Active, not recruiting

Metastatic Gastro-esophageal Adenocarcinoma

Drug: bemarituzumab, trifluridine/tipiracil

Drug: bemarituzumab, irinotecan

Phase 2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Berlin, Germany and 34 other locations

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma (ANTELOPE)

arms. Patients with metastatic TTF-1 negative, treatment-naive lung adenocarcinoma without actionable genomic alterations are randomized in ...

Enrolling

Non-Small Cell Lung Cancer Metastatic

Drug: Cisplatin

Drug: Atezolizumab

Phase 4

Nikolaj Frost MD

Berlin, Germany and 35 other locations

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Active, not recruiting

PDAC - Pancreatic Ductal Adenocarcinoma

PDAC

Drug: 5-fluorouracil

Drug: leucovorin

Phase 3

Revolution Medicines

Berlin, Germany and 59 other locations

Status recently updated

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma...

Begins enrollment this month

Enrolling

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Drug: Nivolumab

Drug: Pumitamig

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)

Berlin, Germany and 160 other locations

Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas (HOLIPANC)

II clinical trial.Eligible patients with hepatic oligometastatic adenocarcinoma of the pancreas will receive neoadjuvant combination chemoth...

Enrolling

Metastasis

Oligometastatic Disease

Drug: nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)

Phase 2

University of Cologne

Berlin, Germany and 10 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Adenocarcinoma in .css-epvm6{white-space:nowrap;}Berlin, BE

Related conditions:

Adenocarcinoma trials near Berlin, BE, DEU:

Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma (NeoART)

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015)

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients (ZANGEA)

Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma (ANTELOPE)

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas (HOLIPANC)

Find clinical trials for Adenocarcinoma in Berlin, BE